StockData
DexCom Inc logo

DexCom Inc (DXCM) stock

DXCMNasdaqSurgical & Medical Instruments & ApparatusFiscal year ends December 31
Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Oct 29, 2026Score 22/3030% below fair value
$82.29+2.36 (+2.95%)

Close on Oct 30, 2026Market cap $31.05BP/E 32.4Yield –

Earnings

DexCom's quarterly results as reported in its earnings releases, with the company's own outlook. Hover a number to see the sentence it came from.

Next report
Feb 11, 2027
Q4 FY2026 · estimated, after the close
Revenue, Q3 FY2026
$1.34B
+11.2% on a year earlier
Non-GAAP diluted net income per share, Q3 FY2026
$0.73
$0.61 a year earlier
Latest guidance
Raised
Oct 29, 2026 · 4 items

Quarterly results

Revenue and earnings per share from each of DexCom's earnings releases, newest first

QuarterReportedRevenueYoYEPSAdj. EPSSource
Q4 FY2026ended Dec 31, 2026Feb 11, 2027Expected–––––
Q3 FY2026ended Sep 30, 2026Oct 29, 2026after the close$1.34B+11.2%$0.72$0.73Release
Q2 FY2026ended Jun 30, 2026Jul 30, 2026after the close$1.31B+13.1%$0.64$0.70Release
Q1 FY2026ended Mar 31, 2026Apr 30, 2026after the close$1.19B+15.0%$0.51$0.56Release
Q4 FY2025ended Dec 31, 2025Feb 12, 2026after the close$1.26B+13.1%$0.68$0.68Release
Q3 FY2025ended Sep 30, 2025Oct 30, 2025after the close$1.21B+21.6%$0.70$0.61Release
Q2 FY2025ended Jun 30, 2025Jul 30, 2025after the close$1.16B+15.2%$0.45$0.48Release
Q1 FY2025ended Mar 31, 2025May 1, 2025after the close$1.04B+12.5%$0.27$0.32Release
Q4 FY2024ended Dec 31, 2024Feb 13, 2025after the close$1.11B+8.2%$0.38$0.45Release
Q3 FY2024ended Sep 30, 2024Oct 24, 2024after the close$994.20M+2.0%$0.34$0.45Release
Q2 FY2024ended Jun 30, 2024Jul 25, 2024after the close$1.00B+15.2%$0.35$0.43Release
Q1 FY2024ended Mar 31, 2024Apr 25, 2024after the close$921.00M+24.2%$0.36$0.32Release

Figures as first announced; later restatements appear under Financials. Expected dates are estimated from the company's past reporting pattern.

Current guidance

DexCom's latest outlook for periods it has not reported yet, compared with what it said before

MetricPeriodGuidanceBeforeChangeGiven
RevenueFY2026$5.20B – $5.25B$5.16B – $5.25BRaisedOct 29, 2026
RevenueFY2026$5.18B – $5.25B$5.16B – $5.25BRaisedJul 30, 2026
Revenue growthFY2026+11% – +13%+11% – +13%ReaffirmedJul 30, 2026
Non-GAAP Gross Profit Marginnon-GAAPFY202664%63% – 64%RaisedOct 29, 2026
Non-GAAP Gross Profit Marginnon-GAAPFY202664%63% – 64%RaisedJul 30, 2026
Non-GAAP Operating Marginnon-GAAPFY202624%22% – 23%RaisedOct 29, 2026
Non-GAAP Operating Marginnon-GAAPFY202623.5% – 24%23% – 23.5%RaisedJul 30, 2026
Adjusted EBITDA Marginnon-GAAPFY202632%30% – 31%RaisedOct 29, 2026
Adjusted EBITDA Marginnon-GAAPFY202631% – 31.5%–NewApr 30, 2026
Adjusted EBITDA Marginnon-GAAPFY202631.5% – 32%–NewJul 30, 2026

Guidance vs results

The last range DexCom gave before each report, against the figure it then reported. Full years add up the four quarters.

PeriodMetricGuidanceActualResult
FY2025Revenue$4.63B – $4.65B$4.66BΣ4QAbove range
FY2025Revenue growth+15%+15.59%Σ4QAbove range

Guidance history

Every forecast DexCom put in an earnings release, newest first

GivenMetricPeriodGuidanceChange
Oct 29, 2026Adjusted EBITDA MarginFY202632%Raised
Oct 29, 2026Non-GAAP Gross Profit MarginFY202664%Raised
Oct 29, 2026Non-GAAP Operating MarginFY202624%Raised
Oct 29, 2026RevenueFY2026$5.20B – $5.25BRaised
Jul 30, 2026Non-GAAP Gross Profit MarginFY202664%Raised
Jul 30, 2026Non-GAAP Operating MarginFY202623.5% – 24%Raised
Jul 30, 2026Adjusted EBITDA MarginFY202631.5% – 32%New
Jul 30, 2026RevenueFY2026$5.18B – $5.25BRaised
Jul 30, 2026Revenue growthFY2026+11% – +13%Reaffirmed
Apr 30, 2026Adjusted EBITDA MarginFY202631% – 31.5%New
Apr 30, 2026Non-GAAP Gross Profit MarginFY202663% – 64%Reaffirmed
Apr 30, 2026Non-GAAP Operating MarginFY202623% – 23.5%Raised
Apr 30, 2026Revenue growthFY2026+11% – +13%Reaffirmed
Apr 30, 2026RevenueFY2026$5.16B – $5.25BReaffirmed
Feb 12, 2026Adjusted EBITDA MarginFY202630% – 31%New
Feb 12, 2026Non-GAAP Gross Profit MarginFY202663% – 64%New
Feb 12, 2026Non-GAAP Operating MarginFY202622% – 23%New
Feb 12, 2026RevenueFY2026$5.16B – $5.25BNew
Jan 12, 2026non-GAAP gross profit marginFY202561%Reaffirmed
Jan 12, 2026Non-GAAP Gross Profit MarginFY202663% – 64%New

Read from the company's earnings releases; each figure links to its sentence on hover. “Raised” and “Lowered” compare with the previous range for the same metric and period.

Press releases

Releases DexCom filed with the SEC as exhibits to Form 8-K or 6-K

  1. Dexcom Reports Third Quarter 2026 Financial Results
    Results
  2. Dexcom Promotes Jereme Sylvain to Chief Operating Officer
    Update
  3. Dexcom Appoints Glenn Boehnlein to Board of Directors
    Update
  4. Dexcom Reports Second Quarter 2026 Financial Results
    Results
  5. Dexcom Reports First Quarter 2026 Financial Results
    Results
  6. Dexcom Appoints Rick Osterloh to Board of Directors
    Update
  7. Dexcom Reports Fourth Quarter and Fiscal Year 2025 Financial Results
    Results
  8. Dexcom Reports Preliminary, Unaudited Results for the Fourth Quarter and Fiscal Year 2025 and Initial 2026 Outlook
    Results
  9. Dexcom Enters Next Era of Continued Innovation with Jake Leach as President and Chief Executive Officer
    Results
  10. Dexcom Reports Third Quarter 2025 Financial Results and Updates Full Year 2025 Guidance
    Results
  11. Dexcom Appoints Euan Ashley to Board of Directors
    Update
  12. Dexcom Reports Second Quarter 2025 Financial Results, Updates Full Year 2025 Guidance and Announces CEO Succession Plan
    Results
  13. Dexcom Reports First Quarter 2025 Financial Results and Announces $750 Million Share Repurchase Program
    Results
  14. Dexcom Appoints Renée Galá to Board of Directors
    Update
  15. Dexcom Reports Fourth Quarter and Fiscal Year 2024 Financial Results
    Results